Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab

xlomafota13 shared this article with you from Inoreader Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab Via In vivo (Athens, Greece) In Vivo. 2021 Nov-Dec;35(6):3563-3568. doi: 10.21873/invivo.12659. ABSTRACT BACKGROUND/AIM: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC). PATIENTS AND METHODS: We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared. RESULTS: Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach me dian progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03). CONCLUSION: CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab. PMID:34697195 | DOI:10.21873/invivo.12659 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.